ΚΑΤΑΣΤΑΣΗ ΤΩΝ ΜΕΓΑΛΥΤΕΡΩΝ GENERIC ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΤΑΙΡΕΙΩΝ ΣΤΙΣ ΗΠΑ
A/A
COMPANY NAME, ADDRESS, PHONE,
FAX
1.
Baxter International
Inc.
1 Baxter Pkwy.
Deerfield, IL 60015-4625
United States
2009 SALES
(MIL. $)
12,562
EMPLOYEES
OVERVIEW
CONTACT
49,700
Why choose between making drugs and
making medical equipment? Baxter
International does it all. The company
makes a wide variety of medical products
across its three divisions, including drugs
and vaccines, dialysis equipment, and IV
supplies. Its BioScience segment makes
protein and plasma therapies to treat
hemophilia and immune disorders, as well
as vaccines and biological sealants used to
close surgical wounds. Baxter is a leading
maker of intravenous (IV) supplies and
systems via its Medication Delivery
segment; the segment also makes infusion
pumps and inhaled anesthetics. Baxter's
Renal division makes dialyzers and other
products for the treatment of end-stage
renal disease (ESRD).
Ludwig Hantson
Phone: 847-948-2000
Fax: 847-948-2016
www.baxter.com
Corporate VP
and President,
International
Baxter has sold off some underperforming
units, including the majority of the services
portion of its Renal division. It also spun off
its Transfusion Therapies business, which
made blood-collection and storage
products, into a new company called
Fenwal in 2007. Fenwal, which still
accounts for some of Baxter's annual
income, is owned by investment firm Texas
Pacific Group.
The company's BioScience segment
accounts for roughly 45% of sales, most of
which comes from the sale of recombinant
1
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
proteins and plasma products used to treat
hemophilia and immune disorders.
Recombinant proteins are useful because
they are derived from DNA that is
manufactured in the laboratory (meaning
greater access to supply). Recombinant
DNA does not exist naturally, but is created
by combining DNA sequences that would
not normally occur together. Among
Baxter's BioScience products are
hemophilia therapy Advate and Aralast NP,
a plasma-derived drug for hereditary
emphysema.
The company increases sales of Advate and
Aralast NP by pushing for greater adoption
of the technology used to make them
through aggressive marketing and
educational campaigns. However, a glut of
plasma-derived products from Baxter and
its competitors combined with the highprice of obtaining such medications has
caused a bit a of market-slowdown which
Baxter intends to fight with a renewed
marketing push aimed at physicians and
hospitals in the US.
The BioScience unit also makes vaccines for
infectious diseases, such as tick-borne
encephalitis and meningococcal meningitis.
Baxter received authorization from the
European Commission in 2009 to market its
pandemic influenza vaccine Celvapan H1N1
in Europe. The vaccine uses Baxter's Vero
cell technology which allows rapid
production and delivery of pandemic
vaccines.
Much of the company's R&D efforts are
focused in the BioScience segment. It has
an ongoing collaboration with Nektar
2
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Therapeutics, for example, to development
blood-clotting proteins using Nektar's
PEGylation technology. And it is working on
other products in areas such as
regenerative medicine and adult stem cell
therapies. To jump into the bone grafting
market, the company spent some $330
million to acquire UK-based ApaTech in
2010. ApaTech's bone grafting materials
are already approved and sold in the US
and Europe. The deal gave Baxter
manufacturing and research facilities in
Germany, the UK, and the US.
Baxter's second largest division, Medication
Delivery, makes intravenous drug delivery
systems, infusion pumps, and anesthesia
products. Products include inhaled and
injectable anesthetics, as well as premixed
drugs and parenteral nutrition products
that are administered intravenously. The
Medication Delivery segment has continued
to see strong growth as demand for IV
solutions and nutritional products has not
seen any signs of slowing, especially in
international markets.
In 2009 Baxter expanded its infusion
systems portfolio by entering into an
agreement to distribute medical device
maker SIGMA's SPECTRUM large volume
infusion pumps domestically and
internationally. The deal also gave Baxter a
40% stake in the company (with the option
to buy the rest of SIGMA over a three-year
period) as well as access to future products
under development.
Along with dialyzers -- dialysis equipment
used primarily in hospitals or clinics -Baxter's Renal division makes home-use
3
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
dialyzers that use a technology called
peritoneal dialysis. The company is betting
on the growth of peritoneal dialysis and
other home-use technologies, especially in
developing markets that don't have the
medical infrastructure needed for clinically
administered dialysis. To that end, it
entered an agreement with HHD and DEKA
Research and Development to produce next
generation home dialyzers. Baxter
expanded further in renal therapies when it
acquired the hemofiltration (renal
replacement therapy) product line of
Edwards Lifesciences in a $65 million deal
in 2009.
The Renal division is also a leading supplier
of heparin, an anticoagulant used during
dialysis and in critical care situations such
as heart surgery. In 2008 Baxter halted
production of heparin, however, after
hundreds of bad reactions (including
several deaths) occurred in patients using
the drug. Subsequent investigations
focused on raw heparin supplied to Baxter
by a Chinese factory, which apparently
added a cheaper ingredient into the drug
which contaminated it. The heparin recall
as well as the end of a marketing and
distribution deal for generic propofol with
Teva Pharmaceutical Industries caused the
company to take a hit in sales in 2008.
With manufacturing operations in more
than two dozen countries and sales
operations all over the world, Baxter
International gets more than half of its
revenue outside the US. Continued
international expansion is key to the
company's growth strategy. It is
4
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
particularly keen on the possibilities of
growing sales of its renal products in
developing countries. It has also set up a
joint venture in China to sell its parenteral
nutrition
2.
Novartis Corporation
608 5th Ave.
New York, NY 10020
United States
n/a
30,186
Phone: 212-307-1122
Fax: 212-246-0185
www.us.novartis.com
3.
Mylan Inc.
5,092.8
15,500
1500 Corporate Dr.
Canonsburg, PA 15317
United States
Phone: 724-514-1800
Fax: 724-514-1870
www.milan.com
Novartis Corporation has what the doctor
ordered. As the North American
headquarters of Switzerland-based Novartis
AG, the unit handles administration, sales,
and marketing for a vast product line of
prescription drugs, consumer health
products, vaccines, and veterinary
products. But wait, there's more! Novartis
Corporation also oversees the Novartis
Institutes for Biomedical Research, which is
headquartered in the US, and charged with
the job of discovering new medicines to add
to the company's ever-expanding pipeline.
Novartis Corporation also headlines dozens
of other US business units including CIBA
Vision, Novartis Pharmaceuticals, and the
US operations of its Sandoz generics
business
Mylan knows you may not recognize
the names of their drugs, but it hopes
you'll appreciate their prices. Through
Mylan Pharmaceuticals, Generics
(UK), and other subsidiaries, the
company is a global manufacturer of
prescription generic drugs, holding a
top 5 position in terms of sales, in
more than a dozen of its worldwide
markets. Mylan's pharmaceutical
cabinet holds antibiotics,
antidepressants, anti-inflammatories,
and laxatives. The company's
Mary
Lou
Mumford
General
Manager
Didier Barret
President,
Europe, Middle
East, and
Africa
5
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
customers include wholesalers,
distributors, retail drugstore chains,
and government agencies. Another
Mylan division, Matrix, is a top
producer of active pharmaceutical
ingredients (APIs) for generic drugs.
Mylan is led by CEO and chairman of
the board Robert Coury.
Mylan makes branded specialty
pharmaceutical products through its Dey
division. The biggest seller in the Dey segment
is the company's EpiPen Auto-Injector, used in
the treatment of severe allergies. EpiPen is an
epinephrine auto-injector and is the #1
prescribed treatment for severe allergic
reactions, with a US market share of more
than 95%.
Mylan's generic pharmaceutical business is
conducted primarily in North America, Europe,
the Middle East, Africa, Australia, and the AsiaPacific region. In the generics segment, 2008
sales to McKesson and Cardinal Health
represented 12% and 10% of total sales.
The company's Mylan Technologies
subsidiary develops and
manufactures generic transdermal
patch products. Another unit, UDL
Laboratories, puts generic drugs into
unit-dose packaging for hospital and
institutional use.
The API business is conducted principally
through Matrix Laboratories in India.
6
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Docpharma, which is a subsidiary of Matrix
Laboratories, is primarily a distributor of
pharmaceutical products in the Benelux region
of Europe.
Mylan is involved in proprietary drug
development through subsidiary Somerset
Pharmaceuticals. Somerset Pharmaceuticals'
primary products are Eldepryl, a drug for the
treatment of Parkinson's disease; and Emsam,
a transdermal patch for major depressive
disorder that is marketed by Bristol-Myers
Squibb.
It was with an eye on global expansion that
Mylan acquired control of Matrix Laboratories
and created the new division to hold it. With
10 manufacturing facilities, it is one of the
largest companies in India and is the world's
largest supplier of generic antiretroviral
pharmaceutical ingredients used to treat
HIV/AIDS. Additionally, by having its own API
producer in-house, Mylan hopes to gain an
edge over competitors, who must obtain their
ingredients from outside manufacturers.
A key piece of Mylan's strategy is to
be the first to file with the FDA to
manufacture generic versions of
popular drugs as they become fair
game. Being first in line gives a
manufacturer a three-month window
of exclusivity, while its competitors
have to wait before they can produce
an equivalent product.
7
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
In its biggest deal yet, Mylan spent
nearly $7 billion to acquire Generics
(UK) Ltd. from Merck. Mylan won out
in a bidding war that included its
major rivals Actavis Group and Teva,
with the prize being a business
almost twice Mylan's size. Following
the acquisition, the company changed
its name from Mylan Laboratories to
just plain Mylan. Akin to a frog
swallowing a salmon, Mylan
estimated it will take two to three
years to fully realize the benefit of
the deal that closed in late 2007.
In 2009 Mylan formed a partnership
with Indian biotech firm Biocon to
expand into the growing field of
generic biotech drugs. The two
companies will co-develop and
market biologic therapies in
numerous countries
4.
Hospira, Inc.
3,879.3
13,500
275 N. Field Dr.
Lake Forest, IL 60045
United States
Phone: 224-212-2000
Fax: 224-212-3350
www.hospira.com
Hospira helps hospitals help the hurting. The
company, a spinoff of drug manufacturer
Abbott Laboratories, makes specialty
injectable pharmaceuticals (primarily generics)
and drug delivery equipment. Its medication
delivery systems include drug pumps, infusion
therapy devices, and related medication
management software. Its injectable drugs
include cardiovascular, anesthesia, and antiinfective therapies. In addition, Hesperia
provides contract manufacturing services for
Ron Squarer
Chief
Commercial
Officer
8
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
injectable pharmaceuticals. A good portion of
Hospira's sales are to group purchasing
organizations (GPOs), including Broadlane,
Novation, and Premier.
Global acquisitions remain a key part of the
company's strategy for future growth, and in
early 2010 it acquired the generic injectable
drug business of India-based Orchid Chemicals
for $400 million. The purchase included a
manufacturing and research facility in India
and a long-term exclusive agreement with
Orchid to supply Hospira with active
pharmaceutical ingredients (APIs). The
company has also announced plans to acquire
drug developer Javelin Pharmaceuticals. The
purchase (worth about $145 million) will give
Hospira access to a new pain medication
Dyloject, which has been submitted to the FDA
for approval.
The deal hit a stumbling block in mid-2010
when Javelin filed suit against Hospira and the
unit formed to acquire Javelin, Discus
Acquisition Corp., alleging that the two failed
to accept and pay for Javelin shares that had
already been tendered and also breached
terms of the two companies' original loan
agreement (under which Hospira was to lend
Javelin $2 million). The suit seeks to compel
Hospira and Discus to complete the
acquisition.
In 2008 Hospira acquired Sculptor
Developmental Technologies, the bar-code
9
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
medication management software business of
St. Clair Health. Hospira continues to use the
St. Clair Hospital in Pittsburgh as a testing and
development site for its medication
administration products. The purchase
contributed to Hospira's efforts to beef up
product offerings in the areas of patient safety
(avoiding medication errors) and clinician
efficiency in health care facilities.
In addition, the company acquired Australian
pharmaceutical maker Mayne Pharma for
about $2 billion a few years ago. The purchase
positioned Hospira as the world's largest
generic injectable drug manufacturer and
significantly expanded its roster of oncology
treatments. Hospira had acquired another
Australian firm, BresaGen, the previous year;
BresaGen conducted biotechnology
therapeutic research.
Hospira's research and development efforts
are focused on creating new generic
pharmaceuticals, as well as new and improved
medication management including IV infusion
pumps and software to control their function.
Hospira has about 15 manufacturing facilities
globally after closing a few to concentrate
manufacturing in other locations, and
outsourcing some production to third-party
suppliers. Its North Carolina, Texas, Kansas,
Costa Rica, and Australia (Victoria) locations
account the majority of output.
In 2009 the company announced corporate
10
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
streamlining measures, including a 10%
workforce reduction by the end of the year.
Hospira also laid out plans to trim its product
line and review options for noncore
operations. Later that year it sold its critical
care product line, with full marketing rights, to
ICU Medical for $35 million. The critical care
business already operated under a
manufacturing partnership between ICU
Medical and Hospira. In early 2010 the
company sold its brain function monitoring
business to SEDLine, a private research firm
backed by Masimo Corporation
5.
Perrigo Company
2,006.9
7,250
515 Eastern Ave.
Allegan, MI 49010 United
States
Phone: 269-673-8451
Fax: 269-673-9128
www.perrigo.com
Perrigo makes its name by making sure you
never see it. One of the US's largest
manufacturers of generic and private-label
over-the-counter pharmaceuticals and
supplements, Perrigo makes products that
use similar packaging and discount pricing
to compete with leading national brands.
The company makes more than 1,300
products, including pain relievers, cough
and cold remedies, dietary supplements,
and smoking cessation products -- some of
which are sold under its own Good Sense
brand. It also makes more than 250
generic prescription products for other
companies. Its Active Pharmaceutical
Ingredients (API) division manufactures the
raw materials used by generic and branded
pharmaceutical companies worldwide.
John Hendrickson
EVP Global
Operations and
Supply Chain
Perrigo's international consumer health
care product subsidiaries Quimica y
Farmacia (Mexico) and Wrafton (UK) offer
over-the-counter and store-brand
11
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
pharmaceutical products. Perrigo
manufactures generic prescription drugs at
facilities in the US and Israel, and
subsidiary Chemagis makes APIs in Israel,
Germany, and China. In 2010 the company
divested its consumer products operations
(but not its manufacturing operations) in
Israel. The business primarily sold
consumer products to the Israeli market,
including cosmetics, toiletries, and
detergents.
Perrigo has grown its pharmaceuticals
business through acquisitions of product
lines it either doesn't have or that would
complement its existing businesses. For
example, in 2008 it expanded its
manufacturing operations by acquiring US
contract OTC drugmaker J.B. Laboratories
for $44 million and Unico Holdings, a US
maker of nutrition and hygiene products,
for $49 million. Both companies have been
integrated into the Perrigo organization.
In a departure from all things
pharmaceutical, in 2010 Perrigo purchased
PBM Holdings, a US-based private
manufacturer and marketer of store-brand
infant formulas and baby foods. The $808
million acquisition took advantage of
Perrigo's existing private-label relationships
with retailers, and gave it a deeper
presence in the OTC consumer products
market.
To expand internationally, the firm has
made purchases abroad including the
acquisition of UK company Galpharm
Healthcare, a manufacturer of store brand
products, in 2008. It then bought Mexican
drugmaker Laboratorios Diba for $25
12
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
million to expand its manufacturing
capacity. In 2010 the company agreed to
acquire Australian OTC products maker
Orion Laboratories for $48 million.
Perrigo's ongoing efforts to introduce a
generic version of Mucinex (guaifenesin)
have been stymied by Mucinex maker
Adams Respiratory, which has filed a
blizzard of patent infringement lawsuits
seeking to protect its lucrative market
niche. The company won the rights to begin
selling a version of Johnson & Johnson's
Monistat vaginal infection product after a
similar series of lawsuits. It plans to begin
marketing the products in 2010.
Along with snapping up other company's
products, Perrigo has its own in-house
research and development team that whips
up generic formulations of name brand
products, as well as responds to changes in
existing national brand products by
reformulating existing company products.
Perrigo's clients include such retailers as
Wal-Mart, CVS, and Walgreen and such
wholesalers as SUPERVALU and McKesson.
Wal-Mart is its largest customer, however,
and accounts for more than 20% of sales.
The company's consumer healthcare
segment has its own sales force to work
with its largest customers.
Vice Chairman Moshe Arkin owns about
10% of Perrigo, and director Michael
Jandernoa holds just over a 3% stake
6.
Boehringer
n/a
6,000
As the US headquarters of German drug
maker Boehringer Ingelheim, Boehringer
Peter Hansbury
13
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Ingelheim
Corporation
Ingelheim Corporation oversees about half
a dozen stateside subsidiaries that produce
and sell drugs (both prescription and overthe-counter), animal health products, and
chemicals for the US market. It sells its
prescription and OTC products through its
largest unit Boehringer Ingelheim
Pharmaceuticals. Additionally, the firm's
Roxane Laboratories makes generic drugs
and its Ben Venue Laboratories is a
contract pharmaceutical manufacturer and
provides drug development services to
other pharmaceutical companies
900 Ridgebury Rd.
Ridgefield, CT 06877
United States
Phone: 203-798-9988
Fax: 203-791-6234
www.us.boehringeringelheim.com
7.
Watson
Pharmaceuticals,
Inc
2,793
5,830
311 Bonnie Cir.
Corona, CA 92880-2882
United States
Phone: 951-493-5300
Fax: 973-355-8301
www.watsonpharm.com
Watson Pharmaceuticals tries to have the
best of both worlds, with operations in the
US generics market and the higher-profitmargin branded drug business. The
company's broad generics portfolio of about
140 products includes treatments for
hypertension and pain, as well as smoking
cessation products, antidepressants, and
oral contraceptives. Its line of about 30
branded drugs focuses on urology and
nephrology; it markets its branded
products, including treatments for iron
deficiency anemia and overactive bladder,
to specialist physicians in the US.
Additionally, Watson distributes its own and
third-party products to independent
pharmacies and health care providers
through its Anda and Valmed subsidiaries.
General
Manager,
Contract
Manufacturing
Division
Thomas Russillo
EVP Global
Generics and
Global
Operations
Watson Pharmaceuticals' bread and butter
is its generics line, accounting for about
60% of sales. An important part of the
company's generics business is its generic
oral contraceptive line. Watson has a
14
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
leading position in the US in generic oral
contraceptives with roughly two dozen
different oral contraceptive products and
about a 35% market share. Its top five oral
contraceptives TriNessa, Low-Ogestrel,
Necon, Lutera, and Microgestin, account for
almost 50% of the total Watson oral
contraceptives portfolio.
The generics business overall has struggled
with the loss of a key product and the
general decline of generics revenue over
time. The big loss came a few years ago
when a distribution agreement with Purdue
Pharma for oxycodone HCl (generic
OxyContin) ended. Name-brand drug
companies sometimes authorize an
"official" generic form when a drug goes
off-patent, in order to recoup some losses
that inevitably result from generic
competition. Watson had distributed the
authorized generic of OxyContin since the
drug lost patent protection in 2005, and the
drug was a big contributor to the
company's revenue.
Watson's strategy for combating declining
sales (as well as the loss of the OxyContin
deal) is to develop and acquire new
products to beef up its pipeline. In 2009
alone the company launched about a dozen
new products including Metoprolol ER to
treat angina, emergency contraceptive
NextChoice, and Galantamine for the
treatment of Alzheimer's disease.
The previous year Watson introduced a
generic version of Biovail's antidepressant
Wellbutrin XL, Johnson & Johnson's
Duragesic pain patch and its Alzheimer
drug Razadyne, Duramed's Mircette oral
15
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
contraceptive, and GSK's Nicorette smoking
cessation gum. Additionally, the company
co-promotes AndroGel, a male hormone
replacement therapy, with Unimed and
distributes an authorized generic of Merck's
Fosamax.
To pick up a few more products, expand its
development pipeline, and broaden its
geographic presence, Watson spent about
$1.75 billion to acquire privately held Arrow
Group in 2009. Arrow develops and
manufactures generic pharmaceuticals in
Canada, Malta, and Brazil and distributes
its products in more than 20 countries.
Major products in the company's branded
drug segment include prostate therapies
Trelstar and Rapaflo. Watson is building its
branded product line through several
partnerships and joint ventures, as well as
through acquisitions of later-stage drug
candidates. Because it relies on
partnerships to augment its product line,
the company's bottom line is also
vulnerable to the expiration of those deals.
For example, Watson lost a key product in
2009 when its license agreement with
Sanofi-Aventis for anemia drug Ferrlecit
ended.
To stave off losses related to losing
licenses, Watson has been trimming costs
by consolidating some operations and
moving some manufacturing operations
overseas. It established a plant in Goa,
India, for example, and has announced the
closures of some US facilities, including the
planned closure of a facility in Carmel, New
York (it will transfer these operations to
Goa). It owns or has invested in plants in
16
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
China and other parts of India and plans to
continue its overseas growth; however,
Watson divested its interest in an API
(active pharmaceutical ingredient) plant in
Taiwan in 2010 after deciding that the
operation was not key to the company's
long-term growth strategy
8.
Forest
Laboratories, Inc
4,192.9
5,200
909 3rd Ave.
New York, NY 10022-4731
United States
Phone: 212-421-7850
Fax: 212-750-9152
www.frx.com
Forest Laboratories doesn't just blend in
with the trees. The company develops and
manufactures name-brand as well as
generic prescription and over-the-counter
pharmaceutical products. The company's
central nervous system (CNS)
pharmaceutical line includes
antidepressants Celexa and Lexapro, as
well as Namenda, which treats Alzheimer's
disease. Other products include treatments
for thyroid disease, hypertension,
respiratory ailments, and pain. Forest
Laboratories markets directly to doctors,
hospitals, drugstore chains, managed care
organizations, and distributors through its
own sales force in the US; it also has
affiliated and independent sales
representatives in the UK and Ireland.
David F. Solomon
VP Business
Development
and Strategic
Planning
Subsidiary Inwood Laboratories promotes
the company's generic products. Nearly
90% of the company's sales revenues come
from large pharmaceutical distributors
McKesson, Cardinal Health, and
AmerisourceBergen, which deliver Forest's
products to customers on a wholesale
basis.
Despite fierce competition from other
established brands, Forest Laboratories has
found a niche in the antidepressant market.
17
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
With Celexa's recent conversion to generic
status, however, the company has become
more dependent on sales of Lexapro, which
accounts for around two-thirds of the
company's revenues. In 2009 Lexapro
received FDA approval for use to treat
depression in adolescents, neatly extending
the brand's potential profitability. Namenda
is another top seller in the CNS field,
accounting for about a quarter of Forest's
sales.
The firm is working to develop and release
new drug candidates that it hopes will
make up for any decline in sales seen from
generic competition. Recent releases
include Bystolic for hypertension treatment
in 2007 and Savella for fibromyalgia in
2009. Its pipeline includes potential drugs
to treat neuropathic pain, gastrointestinal
disorders, asthma, and schizophrenia;
many of the company's development
programs are collaborative efforts with
other pharmaceutical companies.
To bolster its biopharmaceutical research
capabilities, Forest Laboratories purchased
private biotech firm Cerexa for about $494
million in early 2007. Cerexa brought with
it a series of injectable antibiotics under
development to combat bacterial infections
including MRSA (methicillin-resistant
Staphylococcus aureus).
The company ended a co-promotion
agreement with Daiichi Sankyo in 2008 for
the hypertension drug Axor to focus on
sales efforts for its other commercial
products. The two companies have
historically marketed antihypertensive drug
Benicar together; Forest continues to
18
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
receive royalties from the agreement but
has stopped actively marketing the drug.
9.
Falcon
Pharmaceuticals,
Ltd
n/a
3,000
6201 South Fwy.
Fort Worth, TX 761342099 United States
Phone: 817-293-0450
Fax: 800-777-2799
www.falconfharma.com
10.
Mylan
Pharmaceuticals,
Inc
Falcon Pharmaceuticals has a keen eye for
alternatives. The company specializes in
making generic equivalents of ophthalmic
drugs that treat a range of eye conditions,
as well as otic (ear) and nasal ailments. Its
lead product, Timolol GFS, is a generic
equivalent of Merck's glaucoma treatment
Timoptic-XE gel. The company also offers
anti-infective, steroid, anti-viral, antiallergy, and anesthetic pharmaceutical
products without the markup typically
associated with brand names. Falcon
Pharmaceuticals is a subsidiary of eye care
products company Alcon.
Mike Hemrick
VP
The company manufactures about 30
generic formulations of name-brand drugs,
including glaucoma treatment brimonidine,
eye inflammation treatment prednisolone,
and otic and ophthalmic suspensions of
hydrocortisone. Falcon Pharmaceuticals
regularly looks for opportunities to develop
additional products as patented drugs reach
their expiration dates. Alcon formed the
subsidiary in 1994 to develop and market
generic versions of Alcon's and other
drugmakers' products
n/a
2,000
781 Chestnut Ridge Rd.
Mylan Pharmaceuticals isn't a snob when it
comes to labels -- the company is the
generic research and development,
manufacturing, marketing, and distribution
division of Mylan. Mylan Pharmaceuticals
offers more than 200 generic prescription
products developed in-house and through
Larry Salmon
Manager
19
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Morgantown, WV 26505
United States
Phone: 304-599-2595
Toll Free: 800-826-9526
Fax: 304-598-3232
www.mylanpharms.com
distribution agreements with other
pharmaceutical companies. Mylan devotes
most of its research and development
efforts to the creation of extended oral
dosages. Its sister company Mylan
Technologies develops transdermal and
polymer film patches. Its products are sold
to pharmaceutical wholesalers, distributors,
mail order pharmacies, and drugstore
chains.
Mylan Pharmaceuticals is hoping to take
full advantage of its manufacturing
capacity of some 35 million doses as an
aging population combined with efforts to
reduce health care costs, and the resultant
reliance on less-expensive generics
continue to fuel demand in that industry.
The company is also focused on filling a
niche by bringing generics to the US
market that are difficult to formulate or
manufacture, or for which the ingredients
are difficult to obtain. Past examples of
such drugs are pain medication fentanyl,
epilepsy treatment levetiracetam,
psychiatric drug divalproex, and overactive bladder medication oxybutynin.
Those drugs (and others like them)
continue to contribute to the company's
bottom-line, even several years after their
initial launch, because competition
remains limited due to their high barriers
to entry
20
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
11.
Endo
Pharmaceuticals
Holdings Inc
1,460.8
1,487
100 Endo Blvd.
Chadds Ford, PA 19317
United States
Phone: 610-558-9800
Fax: 610-558-8979
www.endo.com
Endo Pharmaceuticals wants the pain to
end, preferably through the drugs it
acquires and markets. The pharmaceutical
company has a portfolio of both branded
and generic prescription products for pain
management. Its best-selling drug is
Lidoderm, a lidocaine patch that treats
nerve pain caused by shingles; it accounts
for about two-thirds of the company's
revenue. Endo also sells well-known pain
meds Percodan and Percocet, as well as
migraine therapy Frova. Its generics
include morphine and oxycodone tablets.
The company markets its drugs in the US
through its own domestic sales force;
however, it outsources almost everything
else, from manufacturing to distribution to
clinical development acitivities.
Sandeep Gupta
VP
Eschewing the integrated business model
favored by most pharmaceutical
companies, Endo has built its business on
alliances with other firms. It in-licenses or
acquires drug candidates and uses contract
research organizations to implement the
clinical development programs it designs. It
also outsources manufacturing (largely to
Novartis Consumer Health and Teikoku
Seiyaku) and warehouse and distribution
activities(to UPS Supply Chain Solutions).
Although the pain management market is
at its core, Endo Pharmaceuticals made a
move to expand into other therapeutic
areas, specifically endocrinology, oncology,
and urology, through its acquisition of
Indevus Pharmaceuticals, a maker of
therapies for ailments including overactive
bladder, hormone disorders, and prostate
21
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
cancer. The 2009 deal cost the company
$370 million, plus potential additional
milestone payments of $267 million. Endo
also gained drug delivery technologies
through the acquisition.
One of the drugs that came with Indevus
was VALSTAR, an approved treatment for
an aggressive form of bladder cancer that
had been shelved years earlier due to
formulation problems. Endo immediately
set to relaunching the product for a quick
return on its investment.
In 2010 the company moved to expand
further in the field of urology when it
agreed to purchase HealthTronics through a
$258 million tender offer and debt
transaction. The acquisition will strengthen
Endo's offering of urological therapies and
expand its operations into the new area of
non-pharmaceutical treatments.
HealthTronics, which will become a wholly
owned subsidiary of Endo, offers medical
equipment including kidney stone
lithotripters, cryosurgery (freezing of
tissue), and diagnostics for prostate
enlargement and cancer, as well as other
urological conditions. The purchase will also
widen Endo's customer base of urological
professionals.
The company's branded prescription
pharmaceuticals, which heavily outweigh its
generics in sales, are marketed to
physicians in anesthesiology, neurology,
oncology, urology, pain management,
primary care, and surgery. It also targets
retail pharmacies throughout the US.
Endo Pharmaceuticals was created in 1997
22
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
through the management buyout of a
pharmaceutical joint venture between
DuPont and Merck
12.
APP
Pharmaceuticals,
LLC
n/a
1,375
1501 E. Woodfield Rd.
Ste. 300 E.
Schaumburg, IL 601735837 United States
Phone: 847-413-2075
Toll Free: 888-386-1300
Fax: 800-743-7082
www.appdrugs.com
Your eyes are getting heavy. You're getting
sleepy. No hypnotist here, just APP
Pharmaceuticals, a company that develops,
makes, and markets anesthetics and other
injectable drugs. Specializing in generics,
APP's critical care products segment
includes market-leading general anesthetic
Diprivan and blood thinner Heparin. Other
product segments focus on injectable
oncology treatments and drugs that fight
ear, heart, respiratory tract, skin, and sinus
infections. APP markets through a direct
sales force and often sells through group
purchasing organizations to customers that
include hospitals, long-term care facilities,
and clinics in North America. The company
is a subsidiary of German medical firm
Fresenius.
Steve Weltler
Manager
The German health care group purchased
APP Pharmaceuticals in 2008 to expand its
global generic injectables business and to
gain entry into the US drug market.
Following the acquisition, APP became part
of the company's Fresenius Kabi division,
which makes infusion therapy and clinical
nutrition products. At the close of 2009 APP
Pharmaceuticals CEO Thomas Silberg
retired, and Fresenius Kabi executive John
Ducker was appointed to the post.
In addition to its marketed generics, APP
Pharmaceuticals has a steady stream of
new drug applications awaiting regulatory
approval and more than 70 product
23
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
candidates in development across its core
oncology, anti-infective, and critical care
categories. Its US research and
development facility focuses on
pharmaceutical formulation, analystical
chemistry, and drug delivery.
American Pharmaceutical Partners Inc.
merged with American BioScience in 2006
to form Abraxis BioScience. In 2007
Abraxis spun off the generic injectables
business as APP Pharmaceuticals, leaving
Abraxis to focus on developing a patented
oncological drug
13.
Ben Venue
Laboratories, Inc
n/a
1,103
300 Northfield Rd.
Bedford, OH 44146-4650
United States
Phone: 440-232-3320
Fax: 440-439-6398
www.benvenue.com
Ben Venue Laboratories prides itself on
having products that are clean, clear, and
cold. A subsidiary of German drug firm
Boehringer Ingelheim, the company
provides contract manufacturing services,
including product and process development
and regulatory compliance services. The
company specializes in manufacturing liquid
and lyophilized (freeze-dried)
pharmaceuticals. Ben Venue's Bedford
Laboratories division provides contract
manufacturing of generic injectable
pharmaceuticals. Customers include
multinational drugmakers, small biotech
development firms, and government
agencies.
Peter Hansbury
General
Manager,
Contract
Manufacturing
Division
The company's Bedford Laboratories
division has expanded its operations as a
contract developer and manufacturer of
generic sterile pharmaceuticals through
internal research and development efforts.
Its products include generic versions of
injectable oncology pharmaceuticals sold
24
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
under the Bedford brand
14.
Amphastar
Pharmaceuticals,
Inc
300
1,040
11570 6th St.
Rancho Cucamonga, CA
91730 United States
Phone: 909-980-9484
Toll Free: 800-423-4136
Fax: 909-980-8296
www.amphastar.com
Amphastar Pharmaceuticals wants to help
drugs help themselves. A maker of
injectable and inhalant drugs and drug
delivery systems, the company focuses on
drugs that are difficult to manufacture or
can be improved with new delivery
systems. Amphastar's products include
Amphadase (increases absorption and
dispersion of injected drugs), Duocaine
(anesthetic for eye surgery), Cortrosyn
(tests for adrenal gland disorders), and
prefilled disposable pipettes (single-dose
dispenser for liquids, creams, and other
forms). The company also offers contract
manufacturing services, including labeling
and packaging, cold storage, and aseptic
filling.
Peter Langosh
VP Operations
The company's Massachusetts-based
Armstrong Pharmaceuticals subsidiary
manufactures metered dose inhalers used
to administer respiratory drugs for asthma
and obstructive pulmonary disease. Along
with generic prescription inhalers and nasal
sprays the company also manufactures the
branded asthma drug Primatene Mist,
which is sold over the counter.
Amphastar's California-based International
Medication systems subsidiary
manufactures pre-filled syringes and vials
with injectable and topical drugs. Its
products range from lidocaine and
morphine used in emergency medicine to
Vitamin K administered to newborn babies
25
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
15.
Teva
Pharmaceuticals
USA
n/a
1,025
1090 Horsham Rd.
North Wales, PA 194541090 United States
Phone: 215-591-3000
Fax: 215-591-8600
www.tevausa.com
When the pharmacist asks you if a generic
equivalent is acceptable, Teva hopes you'll
say "yes." Teva Pharmaceuticals USA, the
US subsidiary of massive Israeli generic
drug maker Teva Pharmaceutical
Industries, develops, manufactures, and
markets both generic and branded
pharmaceuticals. The company is the
largest manufacturer of generic drugs in
the US; its product roster boasts more than
400 generic equivalents of prescription
drugs in a wide variety of therapeutic
categories, including cardiovascular, antiinflammatory, anti-infective, oncology,
central nervous system, and
dermatological.
Robert Jernick
Manager
Teva Pharmaceuticals USA (along with its
cousin to the North, Teva Canada Ltd.)
accounts for about 60% of its parent
company's sales. Teva Pharmaceuticals
USA itself gets about half of its revenues
from direct sales to drugstores and a third
from drug wholesalers; other customers
include mail-order pharmacies, distributors,
and hospitals. Its production capabilities
include a variety of dosage forms, such as
tablets, capsules, ointments, creams,
liquids, injectables, and inhalants.
The company expects US demand for
generics to continue to grow as the
population ages and as the nation
continues to look for ways to reduce
escalating health care costs. To meet that
expected demand and to solidify its position
in the US market, Teva acquired US
generics maker Barr Pharmaceuticals for
$7.5 billion in 2008. Barr's operations were
later integrated into the Teva organization,
26
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
upping Teva Pharmaceuticals USA's annual
prescriptions to about 600 million or more
than 20% of all US generic prescriptions
written.
Teva Pharmaceuticals USA also seeks to
keep its pipeline pumping out generics and
to that end, the company has more than
200 new generic drugs awaiting FDA
approval. Along with performing its own
research and development, the company
forms alliances with other pharmaceutical
firms to license and market generic
versions of their branded drugs. Teva
Pharmaceuticals USA has one such
agreement with Biovail, which expires in
2011, to market three of its hypertension
treatments (Adalat CC, Cardizem CD, and
Procardia XL).
The company's roots go back to Lemmon
Pharmaceutical Company, founded in 1945.
Lemmon Pharmaceutical was acquired by
Teva Pharmaceutical Industries in 1981
16.
Dey, L.P.
n/a
1,000
2751 Napa Valley
Corporate Dr.
Napa, CA 94558 United
States
Phone: 707-224-3200
Fax: 707-224-9264
www.dey.com
Dey helps people breathe easier. The
company, a subsidiary of generic
drugmaker Mylan, makes prescription
drugs for the treatment of allergies and
respiratory diseases. Dey markets EpiPen
autoinjectors, used by patients to selfadminister epinephrine for severe allergic
reactions. Its premeasured unit-dose
inhalation products include treatments for
asthma and chronic obstructive pulmonary
disease (COPD). These treatments, called
bronchodialators, are used in air-driven
breathing devices called nebulizers and
include branded DuoNeb and Perforomist
Garry L. Michaud
SVP Operations
27
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
products. It also offers several non-branded
generic nebulizer treatments. A direct sales
force markets Dey's products to doctors,
pharmacies, and wholesalers.
EpiPen, the company's top product
accounting for more than half of sales, is
the most-prescribed treatment for severe
allergic reactions in the US. Dey launched
its Perforomist inhalation solution for the
treatment of COPD, chronic bronchitis, and
emphysema in 2007. The company plans to
pursue the development and
commercialization of additional product
lines.
In late 2007 former parent Merck KGaA
sold certain generic and specialty
businesses, including Dey, to Mylan for a
whopping $6.7 billion. Merck was looking to
reduce debt from previous acquisitions,
while Mylan boosted its already-stable
position in the global generics market
through the acquisitions. Mylan explored
strategic options for Dey in 2008, but
decided to keep the business later that
year. Mylan plans to restructure Dey's
operations.
Dey started out in 1978 as a purely generic
drug maker, but has expanded over the
years to include branded products. Dey
uses existing respiratory treatments to
develop its patented products using its drug
delivery technologies. It has also directed
R&D efforts towards new dosage and drug
delivery innovations.
Dey is facing some federal and state
lawsuits over alleged false drug-price
28
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
reporting
17.
Roxane
Laboratories, Inc
n/a
1,000
1809 Wilson Rd.
Columbus, OH 43216-6532
United States
Phone: 614-276-4000
Fax: 614-279-5517
www.roxane.com
Mark Edmonds
This Roxane isn't being wooed by Cyrano.
VP Operations
Roxane Laboratories, a US-based
subsidiary of Germany's Boehringer
Ingelheim, oversees the development,
manufacturing, and marketing of its parent
company's generic drug business in the US.
It markets more than 75 medications in
some 250 package sizes, focusing on oral
liquids, sustained-release and controlledrelease tablets, cancer drugs, and nasal
sprays. It also distributes narcotics, such as
meperidine (generic Demerol) and
methadone. Products developed and
marketed by Roxane are manufactured by
its sister company, Boehringer Inghelheim
Roxane, also located in Columbus, Ohio.
Roxane depends on a continual flow
of new drug approvals to refresh its
product lineup. Its research and
development operations aim to file a
steady stream of abbreviated new
drug applications with the FDA. Such
applications simply demonstrate the
company's ability to make
functionally equivalent versions of
existing drugs, and requesting
permission to do so. Recent
approvals included a version of
GlaxoSmithKline's Valtrex (herpes
29
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
simplex, 2010
18.
Sandoz Inc.
135.2
850
506 Carnegie Center
Ste. 400
Princeton, NJ 08540-6243
United States
Phone: 609-627-8500
Fax: 609-627-8659
www.us.sandoz.com
Sandoz, Inc. makes it easier to swallow the
cost of prescription medicines. As the US
arm of Swiss giant Novartis' generic Sandoz
International division, the firm is one of the
largest generic drug makers in the US,
manufacturing more than 200 generic oraldosage drugs. The company's product
portfolio includes drugs to fight infections,
arthritis pain, cardiovascular and
gastrointestinal disorders, and central
nervous system disorders. Sandoz markets
its products to wholesalers, drug stores,
government agencies, HMOs, and hospitals.
The company operates two manufacturing
facilities in the US.
Sharon Jones
Director
Sandoz does more than just manufacturing
of its parent's drugs. It is active in the
research and development of new generics,
shepherding them through testing and FDA
approval, and finally handling the
manufacturing, packaging, and distribution
of the drugs.
Don DeGolyer was appointed CEO of
Sandoz, Inc. in 2010. He replaced Christine
Mundkur who held the position for barely a
year, but steered the company through the
turbulence of the economic recession.
Formerly named Geneva Pharmaceuticals,
the company was brought under the
Sandoz name in 2003 as Novartis sought to
consolidate its generics businesses.
Novartis acquired Eon Labs in 2005 and
integrated it into Sandoz, Inc. to further
strengthen its position in the US generic
30
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
pharmaceutical market.
19.
Impax
Laboratories, Inc.
358.4
801
30831 Huntwood Ave.
Hayward, CA 94544 United
States
Phone: 510-476-2000
Fax: 510-471-3200
www.impaxlabs.com
IMPAX Laboratories hopes that its
combination of generic and branded
pharmaceuticals will make an impact on its
financial health. The company makes
specialty generic pharmaceuticals, which it
markets through its Global Pharmaceuticals
division and through marketing alliances
with other firms, including Teva. It
concentrates on controlled-release versions
of branded pharmaceuticals and niche
pharmaceuticals that require difficult-toobtain raw materials or specialized
expertise. The company's branded
pharmaceuticals business (called IMPAX
Pharmaceuticals) is developing drugs that
target Parkinson's disease, epilepsy, and
other central nervous system disorders.
Peter R. Terreri
Director
The company's Global Pharmaceuticals
division sells its generic products to
wholesalers, chain drug stores, and mail
order pharmacies. IMPAX also works
through strategic alliances; its deal with
Teva, for instance, gives the generics giant
US rights to some versions of its generic
Claritin, Wellbutrin SR, and Prilosec
products
20.
Actavis U.S.
n/a
740
60 Columbia Rd.
Bldg. B
Morristown, NJ 07960
United States
Keeping its parent active in the US is
Actavis US. As its name implies, the
company is the US manufacturing and
marketing unit of global generics firm
Actavis. As such it makes a variety of
generic equivalents of both prescription and
OTC drugs, in a number of forms, including
liquids, tablets, creams, and suppositories.
Ken Hunt
Manager
31
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Phone: 973-993-4500
Fax: 973-993-4303
www.actavis.us
Among other consumer and specialty
drugs, it makes anxiety, depression, and
pain medications. Actavis US has
manufacturing facilities in Maryland, New
Jersey, and North Carolina, from which it
ships its own products and provides
contract manufacturing services to third
parties. Overseeing the US market for its
parent is no small feat, since it comprises
about one third of Actavis' sales.
Some of Actavis US' notable drug releases
have included Kadian, an extended release
pain medication, the generic form of the
antidepressant Wellbutrin XL, and
Levetiracetam, a generic form of Keppra,
an epilepsy drug.
Actavis US ran into some trouble at its
facility in Towata, New Jersey, in 2008 after
the FDA found some manufacturing
violations. The plant issued a voluntary
recall of about 60 medications and worked
with the FDA to meet all of its requirements
before restarting production in 2009. The
company marked the opening by
reintroducing one of its biggest sellers, pain
medication oxycodone, in the US. In 2010
Actavis consolidated its New Jersey
manufacturing operations into its Elizabeth
plant, which resulted in the closure of the
Towata plant. The move came as part of
the company's efforts to cut expenses and
improve operational efficiencies.
Actavis entered North America and created
its US subsidiary in 2005 with three
acquisitions: Amide Pharmaceuticals,
Abrika Pharmaceuticals, and the Human
Generics division of Alpharma
32
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
21.
Caraco
Pharmaceutical
Laboratories, Ltd.
337.2
667
1150 Elijah McCoy Dr.
Detroit, MI 48202 United
States
Phone: 313-871-8400
Fax: 313-871-8314
www.caraco.com
Caraco Pharmaceutical Laboratories is
cooking up cheaper versions of prescription
drugs in the Motor City. The Detroit-based
drug company makes generic knock-offs of
a wide variety of pharmaceuticals,
producing about 60 prescription products in
various strengths and dosages. Its product
lineup includes treatments for high blood
pressure, cancer, nervous system
conditions, diabetes, allergies, and pain.
Indian drugmaker Sun Pharmaceutical
Industries owns about 75% of the firm and
licenses US marketing rights to Caraco for
more than two dozen drugs. Caraco
markets its products throughout the US
and Puerto Rico, selling primarily to
pharmaceutical wholesalers.
The fast-growing company has added to its
product list by focusing on hard-to-make
drugs, as well as therapies that cater to
niche markets such as epilepsy. However, it
is increasingly challenging the validity of
brand-name drug patents, hoping to be the
first to file generic applications with the
FDA, a status that gives drugmakers a
period of market exclusivity.
A majority of the development work for the
company's products is performed at
laboratories in Mumbai and Vadodara, India
operated by Sun Pharmaceuticals. Sun
Pharmaceuticals also supplies Caraco with a
substantial portion of its raw materials for
drug-making.
Along with pharmaceutical wholesalers,
Caraco's products are marketed toward a
wide range of other customers including
33
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
buying groups, retail pharmacies,
distributors, and hospitals. The company's
three largest customers -- AmerisourceBergen, McKesson, and Cardinal Health -combined account for nearly half of its total
sales.
Though the company has experienced
pretty steady growth within its product
lines, it hasn't been without problems. In
2009, the FDA seized more than three
dozen different types of generic drugs from
three manufacturing plants in Michigan due
to what it said were violations of
manufacturing standards having to do with
the size of the tablets being made. The
affected drugs included generic versions of
certain antidiabetic agents, high blood
pressure medicines, and anti-anxiety
medications.
Following the move by the FDA, Caraco
signed a consent decree by which the
company cannot resume manufacturing its
products until it gets written notification
independent experts and the agency. The
stoppage led the company to layoff more
than 400 employees in two phases late in
the year.
Jitendra Doshi became interim CEO of the
company in 2009 following the resignation
of Daniel Movins. Doshi previously served
as Caraco's interim CEO for nearly two
years between 2003 and 2005, prior to the
appointment of Movins
22.
Par
1,193.2
616
Par Pharmaceutical Companies is your
insurance company's resource for cheaper
drugs. The company markets about 70
34
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Pharmaceutical
Companies, Inc.
300 Tice Blvd.
Woodcliff Lake, NJ 07677 United
States
Phone: 201-802-4000
Fax: 201-802-4600
generic drugs in more than 240 dosages;
its generic product line focuses on central
nervous system, cardiovascular, and antiinflammatory medications, as well as
infectious disease. Par manufactures some
of its own products, but in many cases it
distributes drugs manufactured by strategic
partners. The company is moving into the
branded pharmaceutical market as well by
developing updated versions of off-patent
drugs. Its first marketed brand-name
product, Megace ES, treats anorexia and
severe weight loss associated with AIDS;
the drug is a version of a compound owned
by Bristol-Myers Squibb.
In addition to its own portfolio of off-patent
generics, Par Pharmaceutical sells some
authorized generics, which are off-brand
versions of drugs that are sanctioned by
the patent holders. Par has sold an
authorized generic version of diabetes drug
Glucophage, under contract with Bristol
Myers Squibb; it has had other authorized
generic contracts with GlaxoSmithKline for
Flonase and Zantac and with AstraZeneca
for Toprol XL.
In conjunction with a reduction of its
generics business, the company is seeking
to expand its branded products division,
Strativa Pharmaceuticals. To that end it
acquired the rights to develop Nascobal, a
vitamin B-12 nasal spray, in 2009. It
anticipates future company growth will
come from this sort of in-licensing deal.
In 2008 Strativa partnered with Alfacell,
acquiring the US commercialization rights
to that company's investigational cancer
drug, Onconase. The following year it
35
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
signed a similar deal with MonoSol for its
chemotherapy-induced nausea treatment.
Strativa also has an ongoing marketing
relationship with Solvay's for its
testosterone replacement product
Androgel.
Par sells mainly to wholesalers and retail
pharmacy chains; its largest customers,
which account for just over half of
revenues, include drug distributors
McKesson, Cardinal Health, and
AmerisourceBergen
23.
Nycomed US Inc.
257
575
60 Baylis Rd.
Melville, NY 11747 United
States
Phone: 631-454-7677
Fax: 631-454-6389
www.altanainc.com
Nycomed US is the US specialty
pharmaceutical business of Switzerland's
Nycomed International. It operates through
three divisions and is focused on making
and selling drugs for dermatological and
ophthalmic conditions. Its largest division
E. Fougera & Co. primarily makes generic
topical steroids, antibiotics, and
antifungals. It makes both prescription and
over the counter products for use in
hospitals and sale through retailers.
Fougera's sister division PharmaDerm
develops, manufactures, and markets
branded prescription dermatology products.
Nycomed US' Savage Laboratories makes
prescription emergency medicines including
antivenin for snake bites and an antidote
for digitalis poisoning.
Ann Bryant
VP Business
Development
Nycomed US operates a manufacturing
facility in New York and two distribution
centers in Arizona and Pennsylvania.
In 2008 parent Nycomed acquired Bradley
Pharmaceuticals, another US-based niche
player with a focus on dermatology.
36
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Nycomed integrated Bradley's operations -which include sales of branded and generic
drugs -- into Nycomed US's Fougera and
PharmaDerm units.
Formerly owned by ALTANA AG, the
company was bought by Nycomed in 2006,
along with ALTANA AG's other
pharmaceutical operations.
The company had previously grown with
the acquisition of the US dermatology
business of GlaxoSmithKline Consumer
Healthcare. Through the deal, PharmaDerm
added corticosteroid Aclovate, antiinflammatory Cutivate, and antibiotic
Emgel, among other products
24.
Upsher-Smith
Laboratories, Inc
n/a
550
6701 Evenstad Dr.
Maple Grove, MN 55369
United States
Phone: 763-315-2000
Fax: 763-315-2001
www.upsher-smith.com
Upsher-Smith Laboratories (U-S) makes
drugs for us all. Its products include
generic prescription and over-the-counter
medications, focused primarily on the
therapeutic areas of cardiology,
dermatology, and women's health. Among
its cardiology products are folic acid
supplement Folgard, anticoagulant
Jantoven, and heart arrhythmia treatment
Pacerone. It also sells several moisturizers
and cleansers under the AmLactin and
Clenia brand names. The company is also
moving into treatments for diseases of the
central nervous system. Founded in 1919,
U-S maintains manufacturing facilities in
Minneapolis and Denver.
Tom Burke
EVP Commercial
Operations
Looking to expand beyond its traditional
generic market, the company has taken a
small stake in Proximagen Neuroscience, a
British firm that is developing a treatment
for Parkinson's disease. U-S spent about $6
37
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
million for a 7% stake in the company in
hopes of bringing its drug, PRXI, to market.
Its a first step in fulfilling U-S' plans to
introduce four new proprietary drugs by
2017.
The family-owned firm may see its future
plans in jeopardy, however. One more
victim of scam-investor Bernie Madoff, both
the controlling Evenstad family (father and
son Ken and Mark, chairman and CEO,
respectively run the firm) and the
company's profit-sharing fund were heavily
invested in Madoff's Ponzi scheme that
collapsed in late 2008. The FBI froze all
investments when Madoff was arrested.
25.
Paddock
Laboratories, Inc
120
375
108.7
375
3940 Quebec Ave. North
Minneapolis, MN 55427
United States
Phone: 763-546-4676
Fax: 763-546-4842
www.paddocklabs.com
26.
Hi-Tech
Pharmacal Co.,
Inc
Paddock Laboratories can help you corral
all sorts of pharmaceutical goodies. The
company develops and manufactures
bioequivalent generic pharmaceuticals and
OTC specialty products. Paddock's product
line includes suppositories, diabetes
treatments, topical powders, enemas,
injectables, and dermatological offerings,
as well as compounding bases and charcoal
products. Its manufacturing facilities are
located in Minneapolis, Minnesota. In
addition to the US market, some of
Paddock's products are sold in Europe and
the Asia/Pacific region through distributors.
The company was founded in 1977 by
Chairman Bruce Paddock
Hi-Tech Pharmacal combines imitation with
innovation, making and distributing dozens
of liquid and semi-solid prescription, overthe-counter (OTC), and nutritional
products. The company primarily produces
generic forms of prescription drugs,
Ed Maloney
VP Business
Development
Eyal Mares
VP Operations
38
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
369 Bayview Ave.
Amityville, NY 11701
United States
Phone: 631-789-8228
Fax: 631-789-8429
www.hiteckpharm.com
including off-brand versions of antibiotic
Bactrim (made by Roche) and allergy
medicine Flonase (from GlaxoSmithKline),
as well as prescription skin creams,
mouthwashes, and pediatric multivitamins.
Hi-Tech also makes branded over-thecounter products, including a line of
products for diabetes patients and the
Zostrix line of pain and arthritis
medications. In addition, the company has
a handful of branded prescription products.
Hi-Tech's expertise is with difficult-tomanufacture liquid and semi-solid dosage
products, including ophthalmic and inhaled
pharmaceuticals. It provides contract
manufacturing services to other drug firms
needing this specialty. The company's
products are marketed across the US
through large retailers and wholesale
distributors.
Sales of generic drugs bring in about threefourths of Hi-Tech's revenue, and the
company wants to speed up R&D and
regulatory submissions in order to expand
its core prescription drug line. Its generic
product line focuses on oral solutions and
suspensions, creams and ointments, and
nasal sprays, including cough and cold
products and prescription vitamins.
The company also expands its generic
business through acquisitions. The
company widened its product line when it
purchased privately held ECR
Pharmaceuticals for $5.1 million in 2009.
ECR manufactures branded specialty
prescription drugs (allergy, headache, and
dermatitis) and promotes them through an
in-house force of sales representatives
39
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
active in the mid-Atlantic and southern US.
The firm's Health Care Products division,
which handles its branded OTC business,
targets diabetes sufferers with such
products as DiabetiSweet (sugar substitute)
and DiabetiDerm (moisturizing lotion). It
intends to continue developing new
products for its niche diabetes market,
possibly expanding into complementary
areas such as podiatry.
The family of the company's founder
Bernard Seltzer (who died in 2007),
including CEO David Seltzer, own about a
quarter of the firm
27.
Akorn, Inc.
75.9
329
1925 West Field Court
Suite 300
Lake Forest, IL 60045
United States
Phone: 847-279-6100
Fax: 800-943-3694
www.akorn.com
Akorn works hard to grow roots in several
segments of the pharmaceutical industry.
The company makes and sells specialty
therapeutic and diagnostic pharmaceuticals
in categories including ophthalmology,
rheumatology, and anesthesia. Akorn's
ophthalmic segment includes antibiotics,
glaucoma treatments, lubricating
ointments, diagnostic stains and dyes, and
contact lens accessories. The firm's
injectable segment includes drugs for
rheumatoid arthritis and pain management.
Akorn's products are sold nationally to
hospitals, physicians, pharmacies, and
wholesalers. Akorn also provides contract
manufacturing services for other
drugmakers. Chairman John Kapoor
controls about a third of the company.
Steven J. Meyer
Director
The company has internal development
operations, but many of its products are
generic drugs licensed from external
sources. Akorn has teamed with three
40
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
Indian pharmaceutical firms -- Strides
Arcolab, Cipla, and Serum Institute of India
-- to make available to Akorn certain
products (including an oral anti-infective
and some oncology drugs) it can sell to
hospitals and retailers in the US and
Canada.
With the launch of its Tetanus-Diptheria
(Td) vaccine, the company formed a new
operating segment dubbed biologics and
vaccines. The Td vaccine is licensed from
Massachusetts Biologic Laboratories.
Following the successful launch of the Td
vaccine, the company began to market and
distribute an influenza virus vaccine Afluria
(which it licensed from CSL Biotherapies).
Both vaccines are marketed directly to
hospitals and doctors, as well through
wholesalers and distributors.
The company's three biggest customers
account for about half of its sales revenue.
Top customers are Cardinal Health (which
is also one of Akorn's biggest suppliers),
McKesson, and AmerisourceBergen.
Chairman Kapoor is the company's largest
shareholder with a 32% stake, while
Pequot Capital Management owns a 29%
interest in Akorn. When Arthur Przybyl
resigned as CEO in 2009, CFO Jeffrey
Whitnell briefly served as interim CEO
before choosing to leave the company. The
board then appointed newcomers Raj Rai
as interim CEO (and later gave him the
position on a permanent basis) and
Timothy Dick as CFO in mid-2009
41
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
28.
Lannett Company,
Inc.
119
277
9000 State Rd.
Philadelphia, PA 191361615 United States
Phone: 215-333-9000
Fax: 215-333-9004
www.lanett.com
Lannett banks on the designation of
"bioequivalent" for its products. The firm
manufactures and markets generic
prescription drugs such as painkillers
(including two versions of Novartis'
migraine treatment Fiorinal),
anticonvulsants for epileptics, and Digoxin
for congestive heart failure (a version of
Lanoxin). The company has also developed
a generic version of Abbott Laboratories'
Synthroid. While it manufactures some of
its products, Jerome Stevens
Pharmaceuticals manufactures a significant
portion of Lannett's inventories. Lannett
prefers to focus on products with few
generic competitors. Chairman William
Farber and his family own more than half of
the company.
Stephen J. Kovary
VP Operations
Formed in 1942, Lannett is one of the
oldest generics manufacturers in the US.
While the company manufacturers and/or
distributes over 20 different generic drugs,
four formulas account for more than 75%
of its sales. Most of its products are sold as
generics, but some receive private labeling
with a customer's name.
Its customers include the big wholesale US
pharmaceutical distributors as well as
group purchasing organizations, chain drug
stores, and other pharmaceutical
companies. Its largest single customer,
Walgreens, accounted for more than 35%
of sales in 2007.
Lannett holds supply and development
agreements with a handful of domestic and
foreign companies, including Banner
Pharmacaps. It also has agreements for
new product formulation and development
42
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
with other companies, but it intends to
conduct its own manufacturing of any such
products.
The company's 2007 acquisition of Cody
Laboratories expanded its manufacturing
capacity and it has been steadily beefing up
its product development staff to bring more
products through the FDA approval process
29.
Momenta
Pharmaceuticals,
Inc.
20.2
176
675 W. Kendall St.
Cambridge, MA 02142
United States
Phone: 617-491-9700
Fax: 617-621-0431
www.momentapharma.com
Momenta Pharmaceuticals looks to increase
momentum for its drug candidates. The
biotech company specializes in engineering
complex sugars to improve versions of
existing drugs, as well as to discover moreeffective new drugs. By analyzing complex
sugars, the company provides a more
comprehensive picture of the roles sugars
play in cell function, disease, and drug
action. Momenta has several products in
the pipeline, including M-Enoxaparin, a
generic version of heparin drug Lovenox
from Sanofi-Aventis to treat patients with
deep-vein thrombosis and acute coronary
syndromes. The company is also
developing a generic version of multiple
sclerosis treatment Copaxone (marketed by
Sanofi-Aventis and Teva).
Barbara Rosengren
VP
Novartis and its generics arm Sandoz have
teamed with Momenta to develop and
market M-Enoxaparin. This partnership has
been the source of all of the company's
revenues. The two companies are working
to get the drug approved by the FDA.
The company is also developing a
proprietary anticoagulant candidate to treat
cardiovascular ailments including acute
coronary syndromes. Another discovery
43
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
stage program is exploring the role of
complex sugars in cancer treatment.
Momenta Pharmaceuticals was founded in
2001. Novartis owns a 13% stake in the
company
30.
Spectrum
Pharmaceuticals,
Inc
38
158
157 Technology Dr.
Irvine, CA 92618 United
States
Phone: 949-788-6700
Fax: 949-788-6706
www.spectrumpharm.com
Spectrum Pharmaceuticals sees a rainbow
of opportunities in its drug development
pipeline. The drug firm, which focuses on
anti-cancer therapies, won FDA approval in
2008 for its injectable LEVOleucovorin for
use with some osteosarcoma patients; the
drug reduces the toxic effects of a certain
type of chemotherapy. Another
investigational candidate, EOquin, is being
studied as a bladder cancer treatment.
Spectrum has licensed global rights to a
third anti-cancer compound, satraplatin, to
GPC Biotech. Additionally, in 2008 the
company sold to Par Pharmaceutical its
share of profits for the authorized generic
of GlaxoSmithKline's migraine drug
Imitrex; Par had been Spectrum's
marketing partner for the drug.
Michael Adam
SVP
Pharmaceutical
operations
Spectrum has a number of other
investigational drugs in its pipeline, most of
which are focused in the areas of cancer
and urology. And it continues to add
candidates to the mix, usually through inlicensing compounds in later stages of
development. In 2007, for instance, it
licensed ortataxel, a potential cancer
treatment, from Italian drug developer
Indena.
The company has been building its sales
and marketing organization to launch
LEVOleucovorin in the US in 2008. The
44
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010
drug, which the company is also developing
for additional indications such as colorectal
cancer, is already sold outside the US by
Pfizer (through its acquisition of Wyeth)
and Sanofi-Aventis.
Spectrum works and plays well with others.
It formed a collaboration agreement with
Allergan for the development of EOquin for
bladder treatment in 2008. The two
companies will work together to develop
and commercialize the drug; the deal will
earn Spectrum $42 million plus a potential
additional $304 million in milestone
payments.
That same year Spectrum formed RIT
Oncology, a joint venture with Cell
Therapeutics to market that company's
drug Zevalin, a treatment for nonHodgkin's lymphoma. In 2009 Cell
Therapeutics exercised its option to sell the
remaining interest in RIT Oncology to
Spectrum
45
Γραφείο Οικονομικών & Εμπορικών Υποθέσεων Σικάγο, Ιούνιος 2010